<DOC>
	<DOCNO>NCT01065519</DOCNO>
	<brief_summary>Assessment vessel heal DES implantation STEMI , NSTEMI stable/unstable angina patient : randomize comparison everolimus biolimus A9-eluting stent : optical coherence tomography ( OCT ) intravascular ultrasound-tissue characterisation ( IVUS-TC ) study . Plaque characterisation substudy : Assessment culprit lesion different subset patient ( STEMI , NSTEMI stable/unstable angina ) use optical coherence tomography ( OCT ) intravascular ultrasound tissue characterisation ( IVUS-TC ) .</brief_summary>
	<brief_title>STACCATO : Stent sTrut Apposition Coverage Coronary ArTeries : Optical Coherence Tomography ( OCT ) Study</brief_title>
	<detailed_description>1 . The use DES STEMI NSTEMI still matter intense debate . Reassuring data trial , meta-analyses registry conflict report delay arterial healing high risk stent thrombosis DES implantation ACS patient . Heterogeneity healing ( bad heal site necrotic core ) , stent strut malapposition plaque prolapse propose possible cause high risk stent thrombosis . Furthermore , next generation DES claim good safety profile comparison first-generation DES . 2 . Thus far , information tissue characterisation coronary plaque prone rupture , rely histopathology data . Recently , new invasive coronary imaging technique ; radiofrequency intravascular ultrasound ( RF-IVUS ) optical coherence tomography ( OCT ) provide new possibility vivo assessment coronary plaque . Aims : 1 . To evaluate vessel healing , express stent strut coverage stent strut apposition assess OCT 9 month PCI compare everolimus Xience V ( Abbott Vascular , Santa Clara , CA ) biolimus A9-eluting Biomatrix ( Biosensors , Newport Beach , CA ) stent , 3 different group patient subset ( STEMI , NSTEMI patient stable/unstable angina ) . 2 . To make , use OCT IVUS-TC , detailed characterisation coronary lesion PCI study possible link specific lesion characteristic ( e.g . thin cap fibroatheroma , large necrotic core , extensive calcification , â€¦ ) outcome ( risk distal embolisation myonecrosis short term , risk bad strut coverage risk restenosis stent thrombosis long term ) . To compare performance technology ( OCT IVUS-TC ) direct way . 3 . To assess , use OCT IVUS-TC , stented segment intervention ( assessment stent expansion , stent strut apposition , detection edge dissection , intraluminal thrombus ) correlate angiographic clinical outcome . Again , performance technology compare direct way . 4 . To study influence drug-eluting stent implantation 3-5 cm long segment coronary artery distal implant stent use OCT baseline 9 month stent implantation . Methods : Patients undergo PCI recruit 3 group patient : patient STEMI ( group I ) , patient NSTEMI ( group II ) patient stable/unstable angina ( group III ) . From group , 20 patient include . In individual group , randomization everolimus-eluting stent biolimus A9-eluting stent perform . All patient undergo IVUS-TC OCT examination stented segment ( 3 5 cm distal stented segment ) stent implantation time index procedure . All patient undergo control angiography OCT examination 9 month follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patient old 18 year 2 . Written inform consent available 3 . Patient eligible percutaneous coronary intervention 4. patient single multiple de novo lesion ( ) 3 different patient subset ( STEMI , NSTEMI , stable/unstable angina ) . Target reference vessel diameter measure QCA : 24 mm 1 . Left ventricular ejection fraction &lt; 30 % 2 . Hemodynamic unstability ( cardiogenic shock , lifethreatening arrhythmia , inotropic support ) 3 . Impaired renal function ( serum creatinine &gt; 2.0 mg/dl ) 4 . Target lesion locate bifurcation 5 . Lesion leave main trunk &gt; 50 % , unprotected 6 . Known allergy antiplatelet , anticoagulation therapy , contrast medium , everolimus biolimus A9 7 . Pregnant and/or breastfeed female female intend become pregnant ( pregnancy test require ) 8 . Patients life expectancy le one year 9 . Patient currently enrol investigational device drug trial 10 . Patient able willing adhere followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Coronary stent</keyword>
	<keyword>Optical coherence tomography</keyword>
	<keyword>Intravascular ultrasound</keyword>
</DOC>